Brimonidine

What it is

Brimonidine is a small molecule in the same family as clonidine. It is sold in two quite different prescription products that should not be run together. As eye drops (Alphagan P 0.1% or 0.15%, and generics at 0.2%) it lowers pressure inside the eye in glaucoma and ocular hypertension. As a 0.33% gel (Mirvaso) applied to the face it narrows small skin blood vessels to reduce the persistent redness of rosacea. Neither product carries a boxed warning. It is extensively metabolised by the liver and excreted mainly in the urine.

What the research says

As an eye drop it reduces how much aqueous humour the eye makes and increases drainage, lowering intraocular pressure by about 2 to 6 mmHg; a network meta-analysis puts its average reduction at 3.59 mmHg at three months, less than the prostaglandin drops. As a facial gel it constricts skin blood vessels and reduces redness for several hours; the pivotal trials showed a two-grade improvement in roughly a quarter to a third of users versus about a tenth on vehicle. Its main problems are ocular allergy with the eye drops, rebound redness and flushing with the gel, and central nervous system depression in young children.

Evidence grade: Well established.

How it works

Drug class: Relatively selective alpha-2 adrenergic receptor agonist

Brimonidine switches on alpha-2 adrenergic receptors. In the eye this reduces the production of aqueous humour and increases its drainage through the uveoscleral route, so pressure inside the eye falls, peaking about two hours after the drop. In the skin the same receptors sit on small blood vessels, and switching them on narrows the vessels, which is why facial redness fades. Because the receptors also exist in the brainstem, enough systemic absorption causes sedation, slow heart rate and low blood pressure, which is the mechanism behind the toxicity seen in small children. (Source 1)

What it is used for

• A network meta-analysis of 114 randomised trials and 20,275 participants found brimonidine lowered intraocular pressure by 3.59 mmHg (95% credible interval 2.89 to 4.29) at three months, which places it in the middle of the first-line drops, below bimatoprost (5.61 mmHg), latanoprost (4.85) and travoprost (4.83) and similar to timolol (3.70). Evidence: established. (Source 2)
• The Low-Pressure Glaucoma Treatment Study randomised 178 patients to brimonidine 0.2% or timolol 0.5% and found visual field progression in 9.1% on brimonidine versus 39.2% on timolol despite similar treated pressures, which the authors read as a pressure-independent effect. The trial was small, and far more brimonidine patients dropped out from drug-related adverse events (28.3% versus 11.4%), so the authors qualified the conclusion to patients who do not develop ocular allergy. Evidence: limited. (Source 3)
• The Cochrane rosacea review rated the evidence high quality: brimonidine beat vehicle at all time points over 12 hours, with a relative risk of 2.21 (95% CI 1.52 to 3.22) at three hours in one trial and 2.00 (1.33 to 3.01) in the other. In absolute terms the pivotal trials found two-grade composite success in 31% versus 11% (Study 1) and 25% versus 9% (Study 2) at hour 3 on day 29. The effect is temporary and may start to fade within hours of application. Evidence: established. (Source 4)
• A 2-month-old treated with a brimonidine-timolol ophthalmic solution on an ulcerated infantile haemangioma developed life-threatening central nervous system depression and apnoea requiring intubation. The gel label separately warns against applying it to irritated skin or open wounds, and notes post-marketing cases of bradycardia and hypotension in unapproved uses. Evidence: not-supported. (Source 5)

Interactions

• Alcohol and other central nervous system depressants (barbiturates, opiates, sedatives, anaesthetics) (theoretical): Enough brimonidine reaches the bloodstream to act on alpha-2 receptors in the brainstem, so its sedating effect can add to or amplify that of alcohol and other depressants. No formal interaction study has been done for either product; both labels state the possibility should be considered. (Source 6)
• Alcohol and other CNS depressants, with the rosacea gel specifically (theoretical): The gel label carries the same warning as the eye drops. Alcohol is also a well-known flushing trigger in rosacea in its own right, which is a separate matter from the drug interaction. (Source 7)
• Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide) (theoretical): MAO inhibitors could in theory slow brimonidine’s breakdown and increase systemic effects such as low blood pressure. The labels describe this as theoretical and advise caution; no interaction study is cited. (Source 8)
• Blood pressure medicines, beta blockers and digoxin (label): Alpha-2 agonists as a class can lower blood pressure, so the labels for both products advise caution when they are used with beta blockers, other antihypertensives or cardiac glycosides such as digoxin. Post-marketing reports with the gel include bradycardia, hypotension including orthostatic hypotension, and dizziness, some requiring hospital admission. (Source 9)
• Tricyclic antidepressants (amitriptyline, nortriptyline and similar) (theoretical): Tricyclics have been reported to blunt the blood-pressure-lowering effect of clonidine, a close relative. Whether they blunt brimonidine’s eye-pressure-lowering effect in people is not known; the label advises caution. (Source 10)
• Other eye drops applied at the same moment (label): Not a chemical interaction but a practical one: instilling two drops together washes one out. The label says different ophthalmic products should be put in at least 5 minutes apart. (Source 11)
• Food, grapefruit juice and dietary supplements (pharmacokinetic study): We found no documented food, grapefruit or supplement interaction for either brimonidine product in the labels or in the literature we reached. Brimonidine is given into the eye or onto the skin, systemic levels from the gel peak around 46 pg/mL, and it is extensively metabolised by the liver and excreted in urine; no dietary restriction is stated. (Source 12)
• Irritated skin, open wounds and recent laser treatment (gel) (case reports): Applying the gel to damaged skin increases absorption and has been associated with bradycardia, hypotension and dizziness, some requiring hospital admission; the label tells users to avoid it. (Source 13)

Stopping it

• There is no withdrawal syndrome or taper requirement in either label. For the rosacea gel there is a rebound issue on stopping and during treatment: the label records that some subjects reported erythema returning worse than at baseline, and that erythema appeared to resolve after the gel was discontinued. (Source 14)
• A published case documents the same pattern: progressive worsening of baseline redness hours after each application, temporarily masked by applying more gel, and improvement only once the gel was stopped. The author proposed the name "dermatitis medicamentosa" by analogy with rhinitis medicamentosa from decongestant nasal sprays. (Source 15)
• For the eye drops, stopping matters in the other direction: the Low-Pressure Glaucoma Treatment Study lost 28.3% of brimonidine patients to drug-related adverse events versus 11.4% on timolol, so for many people treatment ends because of ocular allergy rather than by choice, and the trial’s favourable conclusion was limited to those who did not develop it. (Source 3)
• The gel label also requires discontinuation if a clinically significant hypersensitivity reaction occurs; post-marketing reports include angioedema, throat tightening, tongue swelling and urticaria. (Source 16)

What goes wrong

Ocular allergy and eye irritation are the characteristic adverse effects of brimonidine eye drops, affecting 10% to 20% of users in trials. (Source 17)

• Official position, Moderate certainty.
• Size: pooled clinical trial experience with brimonidine ophthalmic solution 0.1% to 0.2%.
• Who: adults treated for glaucoma or ocular hypertension.
• How long: trial durations not stated in this section.
• Result: allergic conjunctivitis, conjunctival hyperaemia and eye pruritus each in approximately 10% to 20%; burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness and visual disturbance in approximately 5% to 9%.
• Funding: manufacturer labeling (Allergan, Inc.)

Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

In a label-reported paediatric study, brimonidine eye drops made a large proportion of young children drowsy, and the drops are contraindicated under the age of 2 because of reports of apnoea, bradycardia and coma in infants. (Source 18)

• Official position, Moderate certainty.
• Size: a well-controlled study in paediatric glaucoma patients aged 2 to 7, plus post-marketing surveillance.
• Who: children aged 2 to 7 with glaucoma; post-marketing reports in infants.
• How long: study duration not stated in this section.
• Result: somnolence in 50% to 83% of children aged 2 to 6 on brimonidine 0.2% three times daily; 25% in those aged 7 and over above 20 kg; about 16% discontinued because of somnolence; apnoea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor and respiratory depression reported in infants.
• Funding: manufacturer labeling (Allergan, Inc.)

Limit of this finding: The label's own age bands do not line up. It describes the study as having been conducted in children aged 2 to 7, then reports the drowsiness results for children aged 2 to 6 (50% to 83%) and for children aged 7 and older weighing more than 20 kg (25%) — the second of which reaches past the ages it says were enrolled. The percentages are the label's and are reproduced exactly; which ages each one applies to is not stated consistently in the source. The contraindication below the age of 2 and the infant reports are unaffected by this.

In a well-controlled clinical study conducted in pediatric glaucoma patients aged 2 to 7 years old, the most commonly observed adverse reactions with brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence (50% to 83% in pediatric patients aged 2 to 6 years old) and decreased alertness. In pediatric patients aged 7 years and older (greater than 20 kg), somnolence appears to occur less frequently (25%). Approximately 16% of pediatric patients on brimonidine tartrate ophthalmic solution 0.2% discontinued from the study due to somnolence.

Systemic alpha-2 agonist poisoning from brimonidine eye drops has been documented in children, including bradycardia with altered mental status requiring intensive care. (Source 19)

• Case series, Very low certainty.
• Size: 3 paediatric patients (2 apraclonidine, 1 brimonidine)
• Who: children presenting to emergency care.
• How long: acute presentations.
• Result: one case of bradycardia and altered mental status requiring intensive care monitoring from therapeutic ophthalmic application of brimonidine; the series describes sympatholytic effects including CNS and respiratory depression, hypotension, bradycardia, miosis, hypothermia and hyporeflexia.
• Funding: not stated in the abstract.

Three pediatric patients presented with systemic central alpha-2 agonist poisoning-2 cases of bradycardia and apnea resulting from ingestion of ingestion of apraclonidine, with 1 case requiring intubation, and 1 case of bradycardia and altered mental status requiring intensive care monitoring resulting from therapeutic ophthalmic application of brimonidine.

A 2-month-old given a brimonidine-containing ophthalmic solution topically on an ulcerated haemangioma, an unapproved use, developed life-threatening toxicity. (Source 5)

• Case report, Very low certainty.
• Size: 1 infant.
• Who: a 2-month-old girl with an ulcerated infantile haemangioma.
• How long: single case.
• Result: central nervous system depression and apnoea requiring intubation and mechanical ventilation.
• Funding: not stated in the abstract.

We report the case of a 2-month-old girl who developed life-threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.

Rebound redness is a documented problem with the rosacea gel: the label records that some trial subjects had erythema return worse than at baseline, and that the treatment effect may fade within hours. (Source 14)

• Official position, Moderate certainty.
• Size: clinical trial and post-marketing reports.
• Who: adults using brimonidine 0.33% gel for rosacea.
• How long: onset of flushing ranged from about 30 minutes to several hours after application.
• Result: no rate given in this section; the label states some subjects discontinued because of erythema and some reported a rebound phenomenon.
• Funding: manufacturer labeling (Galderma Laboratories, L.P.)

Some subjects in the clinical trials discontinued use of MIRVASO topical gel because of erythema. Some subjects in the clinical trials reported a rebound phenomenon, where erythema was reported to return worse compared to the severity at baseline.

In the pivotal rosacea trials the excess of erythema and flushing over vehicle was small, but over a year of use flushing and erythema were reported by 10% and 8% of users. (Source 20)

• Official position, Moderate certainty.
• Size: 330 on gel and 331 on vehicle in the 29-day vehicle-controlled trials; 276 applied the gel for at least one year in the open-label study.
• Who: adults with persistent facial erythema of rosacea.
• How long: 29 days (controlled) and up to one year (open-label)
• Result: erythema 12 of 330 (4%) versus 3 of 331 (1%); flushing 9 (3%) versus 0; skin burning sensation 5 (2%) versus 2 (1%); at one year flushing 10%, erythema 8%, rosacea 5%, skin burning sensation 4%, increased intraocular pressure 4%.
• Funding: manufacturer labeling (Galderma Laboratories, L.P.)

Erythema | 12 (4%) | 3 (1%) Flushing | 9 (3%) | 0 Skin burning sensation | 5 (2%) | 2 (1%) Dermatitis contact | 3 (1%) | 1 (<1%)

A manufacturer-conducted retrospective review of the same trials found worsening redness in 5.4% of subjects in the pivotal studies and 15.4% in the long-term study, and characterised these events as infrequent and transient. (Source 21)

• Expert review, not systematic, Low certainty.
• Size: subjects in the two pivotal four-week Phase 3 studies and the 52-week long-term safety study.
• Who: adults with erythema of rosacea.
• How long: 4 weeks and 52 weeks.
• Result: flushing and erythema in 5.4% of subjects in the Phase 3 studies and 15.4% in the long-term study; most events mild or moderate, transient and intermittent, occurring early in treatment.
• Funding: industry: a retrospective review of the manufacturer’s own clinical studies, published in a journal supplement.

Limit of this finding: The paper's conclusion and its own results pull in different directions: it concludes that adverse events of worsening redness "are not frequent" while reporting flushing and erythema in 15.4 percent of subjects in the year-long study. Fifteen in a hundred is not obviously infrequent, and the two statements sit in the same abstract. This is also a retrospective review of the manufacturer's own trial programme with no funding statement, so it is not independent safety surveillance.

Flushing and erythema were the most commonly reported adverse events, occurring in a total of 5.4 percent of subjects in the Phase 3 studies and in 15.4 percent in the long-term study.

An independent case report documents severe rebound erythema on the gel that worsened hours after each application and resolved only on stopping the drug. (Source 15)

• Case report, Very low certainty.
• Size: 1 patient.
• Who: a 28-year-old woman with long-standing untreated erythematotelangiectatic rosacea.
• How long: single case.
• Result: initial improvement followed by progressive worsening of baseline erythema several hours after treatment, temporarily relieved only by further applications; resolved on discontinuation.
• Funding: not stated in the abstract.

Initial improvement was followed by progressive worsening of baseline erythema several hours following treatment, only improved with subsequent applications of additional Mirvaso. The patient's symptoms were improved upon discontinuing use of Mirvaso.

Brimonidine eye drops have been linked after marketing to slow heart rate, fainting, depression and dry eye, with frequencies that cannot be estimated. (Source 22)

• Official position, Low certainty.
• Size: spontaneous post-approval reports of unknown denominator.
• Who: users of brimonidine tartrate ophthalmic solutions.
• How long: post-approval period.
• Result: no rates can be calculated; the label states frequency cannot be reliably estimated.
• Funding: manufacturer labeling (Allergan, Inc.)

Bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (including erythema, eyelid pruritus, rash, and vasodilation), syncope, and tachycardia.

What the evidence supports

Brimonidine eye drops lower intraocular pressure, by an average of 3.59 mmHg at three months, placing them below the prostaglandin analogues. (Source 2)

• Meta-analysis, Moderate certainty.
• Size: 114 randomised controlled trials with data from 20,275 participants.
• Who: people with primary open-angle glaucoma or ocular hypertension.
• How long: 3 months.
• Result: brimonidine 3.59 mmHg (95% credible interval 2.89 to 4.29); bimatoprost 5.61 (4.94 to 6.29); latanoprost 4.85 (4.24 to 5.46); travoprost 4.83 (4.12 to 5.54); timolol 3.70 (3.16 to 4.24)
• Funding: not stated in the abstract; the authors note overall risk of bias in the included trials is mixed.

The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.24), tafluprost 4.37 (2.94; 5.83), timolol 3.70 (3.16; 4.24), brimonidine 3.59 (2.89; 4.29), carteolol 3.44 (2.42; 4.46), levobetaxolol 2.56 (1.52; 3.62), apraclonidine 2.52 (0.94; 4.11), dorzolamide 2.49 (1.85; 3.13), brinzolamide 2.42 (1.62; 3.23), betaxolol 2.24 (1.59; 2.88), and unoprostone 1.91 (1.15; 2.67).

Topical brimonidine gel reduced facial redness of rosacea more than vehicle at every time point over 12 hours, with high-quality evidence. (Source 4)

• Systematic review, High certainty.
• Size: 2 randomised vehicle-controlled trials within a review of 106 studies and 13,631 participants.
• Who: adults with moderate to severe persistent facial erythema of rosacea.
• How long: 4 weeks of once-daily treatment, assessed over 12 hours per day.
• Result: participants’ assessments at three hours RR 2.21 (95% CI 1.52 to 3.22) and RR 2.00 (95% CI 1.33 to 3.01) in favour of brimonidine.
• Funding: Cochrane review; the individual trials were manufacturer-sponsored.

Topical brimonidine in two studies was more effective than vehicle in reducing erythema in rosacea at all time points over 12 hours (high quality evidence). At three hours the participants' assessments had a RR of 2.21 (95% CI 1.52 to 3.22) and RR of 2.00 (95% CI 1.33 to 3.01) in favour of brimonidine. Physicians' assessments confirmed these data.

What the evidence does not support

That same analysis shows brimonidine is not among the most effective first-line drops, although the authors say within-class differences may not be clinically meaningful. (Source 2)

• Meta-analysis, Moderate certainty.
• Size: 114 randomised controlled trials, 20,275 participants.
• Who: people with primary open-angle glaucoma or ocular hypertension.
• How long: 3 months.
• Result: brimonidine ranked seventh of fourteen drugs for pressure reduction at 3 months.
• Funding: not stated in the abstract.

All active first-line drugs are effective compared with placebo in reducing IOP at 3 months. Bimatoprost, latanoprost, and travoprost are among the most efficacious drugs, although the within-class differences were small and may not be clinically meaningful.

Where the evidence is mixed

In low-pressure glaucoma, far fewer patients on brimonidine had visual field progression than on timolol despite equal pressures, but many more stopped the drug because of side effects. (Source 3)

• Randomized trial, Low certainty.
• Size: 178 patients randomised (99 brimonidine, 79 timolol)
• Who: patients with low-pressure (normal-tension) glaucoma, untreated IOP 21 mmHg or less.
• How long: mean follow-up 30.0 months (SE 2)
• Result: field progression 9 of 99 (9.1%) on brimonidine versus 31 of 79 (39.2%) on timolol (log-rank 12.4, P=.001); treated IOP similar at all time points; discontinuation for drug-related adverse events 28 of 99 (28.3%) versus 9 of 79 (11.4%), P=.008.
• Funding: not stated in the abstract.

Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001). Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points. More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).

The absolute benefit in the pivotal rosacea trials was modest: roughly a quarter to a third of users reached the two-grade success endpoint, against about a tenth on vehicle. (Source 23)

• Official position, Moderate certainty.
• Size: Study 1: 129 on gel, 131 on vehicle. Study 2: 148 on gel, 145 on vehicle. 553 subjects in total.
• Who: adults 18 and over with moderate to severe persistent facial erythema of rosacea; 99% Caucasian, 76% female.
• How long: 4 weeks once daily, assessed on day 29.
• Result: two-grade composite success at hour 3 on day 29: 31% versus 11% (Study 1) and 25% versus 9% (Study 2); at hour 12, 23% versus 9% and 22% versus 10%.
• Funding: manufacturer labeling (Galderma Laboratories, L.P.)

Table 2: Summary of 2-grade Composite Success on Day 29 Success | Study 1 | Study 2 | MIRVASO Topical Gel (N=129) | Vehicle Gel (N=131) | MIRVAO Topical Gel (N=148) | Vehicle Gel (N=145) Hour 3 | 31% | 11% | 25% | 9%

A manufacturer-funded expert panel concluded that about 80% of people treated with brimonidine gel improve without worsening erythema, and set out candidate mechanisms for the rest. (Source 24)

• Expert review, not systematic, Very low certainty.
• Size: not a study; a meeting of dermatologists and receptor and neuroimmunology scientists.
• Who: people treated with brimonidine gel for rosacea.
• How long: not applicable.
• Result: approximately 80% experience significant improvement without erythema worsening as an adverse event; four candidate mechanisms proposed.
• Funding: industry-funded: Galderma International S.A.S., Paris, France.

Approximately 80% of patients treated with brimonidine experience a significant improvement without erythema worsening as an adverse event.

Where the research disagrees

Whether topical brimonidine gel causes rebound or worsening erythema

• van Zuuren and colleagues, Cochrane review of interventions for rosacea (2015), systematic review; the statement rests on the two four-week manufacturer-sponsored pivotal trials included in the review: There was no rebound or worsening of erythema after treatment cessation. (Source 4)
• The MIRVASO prescribing information (Galderma Laboratories, SPL version 11, effective 24 October 2024), regulatory labeling drawing on the same trials plus post-marketing reports, which also describe erythema spreading to previously unaffected areas: Some subjects in the clinical trials reported a rebound phenomenon, where erythema was reported to return worse compared to the severity at baseline. (Source 14)
• Werner and Kobayashi, case report in Dermatology Online Journal (2015), single photo-documented case report; the weakest design of the three, and not a basis for a rate: Rebound erythema secondary to use of topical brimonidine in the setting of rosacea is an important, possibly significantly distressing potential side effect that may be under-reported (Source 15)

How much

• Reference intake: Dosing is set by the prescriber, not by the reader, and the two products are different. The eye drop label records as a position one drop in the affected eye(s) three times daily about 8 hours apart (Allergan labeling, SPL version 25, effective 18 September 2025). The rosacea gel label records a pea-sized amount once daily to each of five areas of the face (Galderma labeling, SPL version 11, effective 24 October 2024). (Source 11)
• Upper limit: No maximum total daily dose is stated for either product beyond the dosing frequency itself. The gel label records as a position that it is for topical use only and not for oral, ophthalmic or intravaginal use, and that it should be kept out of reach of children. (Source 25)
• Studied: The Low-Pressure Glaucoma Treatment Study used brimonidine tartrate 0.2% twice daily in both eyes versus timolol maleate 0.5% twice daily, over a mean of 30 months. (Source 3)
• Studied: The clinical studies behind Alphagan P compared brimonidine tartrate ophthalmic solution 0.15% and 0.1% with Alphagan 0.2%, each administered three times daily. (Source 26)
• Studied: The two pivotal rosacea trials gave brimonidine 0.33% gel or vehicle once daily for 4 weeks to 553 adults, and an open-label study ran once-daily treatment for up to one year in 276 subjects. (Source 23)

A common belief, and what the research shows

The belief: Brimonidine is one drug, so the eye drops and the rosacea gel behave the same way, and because they are applied to the surface they cannot do anything to the rest of the body.

What the research shows: They are different products with different approved uses, concentrations and problems, and surface application is not the same as no systemic exposure. The eye drops are contraindicated in children under two years old, and in children aged 2 to 6 given the 0.2% drops three times daily, somnolence occurred in 50% to 83%. Three paediatric systemic poisonings from central alpha-2 agonist eye drops have been published, one from therapeutic brimonidine use, and an infant given a brimonidine-containing ophthalmic solution on an ulcerated haemangioma needed intubation. The gel’s own distinct problem is rebound: the label records that erythema was reported to return worse than at baseline in some trial subjects, which the Cochrane review did not find in the four-week trials.

Questions and answers

What is it?

Brimonidine is an alpha-2 adrenergic agonist, chemically related to clonidine. It comes as prescription eye drops for glaucoma and raised eye pressure, as a 0.33% facial gel for the persistent redness of rosacea, and at a lower strength over the counter for eye redness. It is extensively metabolised by the liver and excreted mainly in urine. (Source 1)

What does it do in the body?

In the eye it both reduces the amount of fluid the eye produces and increases its drainage, which lowers the pressure inside the eye by roughly 2 to 6 mmHg. On the face it narrows small skin blood vessels, which reduces redness for a few hours. The same receptor exists in the brainstem, which is why enough systemic absorption causes drowsiness, a slow heart rate and low blood pressure. (Source 1)

Is it good or bad for you?

It depends on the product, the person and the age. For adults with glaucoma it meaningfully lowers eye pressure, though less than prostaglandin drops, and allergic conjunctivitis affects 10% to 20%. For adults with rosacea redness the gel works for several hours in a minority who reach the trial endpoint, with rebound redness as the distinctive problem. In infants and young children the drops are hazardous: contraindicated under age 2, and somnolence in 50% to 83% of 2-to-6-year-olds treated. (Source 18)

How do you get more of it?

Both prescription products are prescriber-directed and no dose is suggested here. The eye drop label records as a position one drop in the affected eye(s) three times daily, about 8 hours apart, and that it may be used alongside other pressure-lowering drops if they are instilled at least five minutes apart. The gel label records a pea-sized amount once daily spread thinly across five areas of the face, avoiding eyes and lips. (Source 11)

If it is harmful, what reduces it?

Systemic brimonidine has a short half-life of about 2 hours after an eye drop, and it is cleared by liver metabolism and urinary excretion, with about 87% of an oral dose eliminated within 120 hours. Where the gel is causing rebound redness, the label records that the erythema appeared to resolve after the gel was discontinued. In overdose or poisoning there is no antidote named: treatment is supportive with attention to the airway. (Source 27)

Why might someone be low in it or missing it?

These are medicines rather than nutrients, so "missing" means not prescribed, stopped, or withheld. The commonest reason brimonidine is stopped is that the person cannot tolerate it: in the Low-Pressure Glaucoma Treatment Study 28.3% of brimonidine patients withdrew because of drug-related adverse events, against 11.4% on timolol. For the eye drops it is also withheld by rule in children under 2 and in anyone who has had a hypersensitivity reaction to it. (Source 3)

Which whole foods contain it or feed it?

No whole food contains brimonidine and no food is documented to raise or lower it. Systemic exposure from the gel is tiny: in 24 adults applying 1 gram to the whole face daily for 29 days, peak plasma concentration averaged 46 pg/mL. For people using the gel for rosacea, the food question that matters is their own flushing triggers rather than any drug interaction, and the literature we reached does not quantify that for brimonidine users. (Source 23)

What happens if you do not have it?

Nobody needs brimonidine physiologically. For someone with glaucoma, not treating raised eye pressure is what matters: the label states that the higher the pressure, the greater the likelihood of optic nerve damage and visual field loss. For someone using the gel, stopping means the redness returns to its own baseline, and in some people transiently worse before it settles. (Source 26)

How can you test for it?

There is no routine test for brimonidine itself. What is measured is its effect. For the eye drops that is intraocular pressure by tonometry plus standard automated perimetry for the visual field; the Low-Pressure Glaucoma Treatment Study used exactly those at four-month intervals, with progression defined by pointwise linear regression over three consecutive tests, which is a reminder that single readings are noisy and trends over repeated tests are what count. For the gel the endpoints are graded redness scales rather than any laboratory test. (Source 3)

References

1. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 12.1 Mechanism of Action. 2025. Read the source
2. Ophthalmology. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.. 2016. PMID 26526633, DOI 10.1016/j.ophtha.2015.09.005. Read the source
3. Am J Ophthalmol. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.. 2011. PMID 21257146, DOI 10.1016/j.ajo.2010.09.026. Read the source
4. Cochrane Database Syst Rev. Interventions for rosacea.. 2015. PMID 25919144, DOI 10.1002/14651858.CD003262.pub5. Read the source
5. Pediatr Dermatol. Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma.. 2016. PMID 27282306, DOI 10.1111/pde.12868. Read the source
6. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 7.2 CNS Depressants. 2025. Read the source
7. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 7.2 CNS Depressants. 2024. Read the source
8. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 7.4 Monoamine Oxidase Inhibitors. 2025. Read the source
9. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 7.1 Anti-hypertensives/Cardiac Glycosides. 2024. Read the source
10. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 7.3 Tricyclic Antidepressants. 2025. Read the source
11. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 2 DOSAGE AND ADMINISTRATION. 2025. Read the source
12. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 12.3 Pharmacokinetics. 2025. Read the source
13. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 5.4 Systemic Adverse Reactions of Alpha-2 Adrenergic Agonists. 2024. Read the source
14. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 5.5 Local Vasomotor Adverse Reactions. 2024. Read the source
15. Dermatol Online J. Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea.. 2015. PMID 25780983. Read the source
16. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 6.2 Postmarketing Experience. 2024. Read the source
17. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 6.1 Clinical Trials Experience. 2025. Read the source
18. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 8.4 Pediatric Use. 2025. Read the source
19. Pediatr Emerg Care. Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings.. 2008. PMID 18347496, DOI 10.1097/PEC.0b013e3181668aee. Read the source
20. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 6.1 Clinical Trials Experience. 2024. Read the source
21. J Clin Aesthet Dermatol. Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies.. 2015. PMID 26345379. Read the source
22. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 6.2 Postmarketing Experience. 2025. Read the source
23. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 14 CLINICAL STUDIES. 2024. Read the source
24. Adv Ther. Multidisciplinary Consideration of Potential Pathophysiologic Mechanisms of Paradoxical Erythema with Topical Brimonidine Therapy.. 2016. PMID 27562835, DOI 10.1007/s12325-016-0404-8. Read the source
25. Galderma Laboratories, L.P. / U.S. National Library of Medicine DailyMed. MIRVASO (brimonidine) topical gel, 0.33% - FDA prescribing information (DailyMed SPL), 2 DOSAGE AND ADMINISTRATION. 2024. Read the source
26. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 14 CLINICAL STUDIES. 2025. Read the source
27. Allergan, Inc. / U.S. National Library of Medicine DailyMed. ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% / 0.15% - FDA prescribing information (DailyMed SPL), 10 OVERDOSAGE. 2025. Read the source